Projects leaders can apply at any time. If interested, candidates (academics or startups) apply to the programme by submitting an application form. According to their specific needs, applicants may benefit from several steps of the programme.
Since September 2018, non-French European applicants can apply if they can prove that they have collaboration with French partners (academic team or company).
Outreach session :
This session is open to every cancer innovation project leader (candidates or not). The stated goal is to allow participants to identify main challenges, constraints and key success factors in the development of cancer innovation (therapy, diagnostic or medical device), from research to early clinical stage through various thematic areas (strategic framework, business plan, key success factors from preclinical development to early clinical stage, regulatory framework, patent strategy, maturation funding, etc…), through concrete examples.
This session takes place once a year in September in Paris with high quality speakers selected for their skills within the different approached subjects.
Pitchs selection:
Once the application file has been submitted to MATWIN, the project can be selected for a pitch presentation before a multidisciplinary jury meeting at the beginning of December in Paris.
The projects selected by the experts will then be submitted to the MATWIN International Board members (on the basis of the application dossier), who will be the ones deciding which projects can be included in the programme.
The written comments of the MATWIN Board members will be sent to all applicants by end of January.
On the basis of experts assessments, projects are invited or not to continue the process (coaching) for a possible presentation at the MATWIN International Board meeting at the end of the process. Projects are not competing against each other, only intrinsic value and development potential are taken into account.
The pre-selection pitches will take place in Paris on 17 & 18 December 2018!
Composition of the pre-selection jury:
- Jean-Yves Bonnefoy(Syndivia);
- Gilles Avenard (Acticor Biotech);
- Jean-Marc Herbert (Go Capital);
- Jean-Pierre Armand (Gustave Roussy);
- Sergio Roman Roman (Institut Curie);
- Maryvonne Hiancé (OSE Immunotherapeutics / France Biotech);
- Stéphane Loze (Angels Santé );
- Benoit Barteau (BPI France)
Coaching sessions :
Individual work sessions are frequently organized to optimize projects’ structuring and industrial orientation. Technology transfer offices are associated and included in the process. They are invited to participate to every working session organized by MATWIN next to the project leaders to benefit from the feedback.
Development Plan Review
Driven by innovation specialists and experts in preclinical and clinical development, this work session addresses the project’s background and allows to optimize its structure and industrial orientation. This session aims at supporting projects leaders in their valorization approach.
It takes place once a year in February/March in Paris.
Training for the Board meeting audition
This second work session aims at preparing the project leader for his interview by the MATWIN International Board strengthened by the 1st session contributions. Experts speakers bring their expertise to optimize the project presentation. This session is in a real condition format (in English, in front of a multidisciplinary jury) to reflect the MATWIN Board interview.
By end of the two coaching sessions, the coaches will select the 6 best projects that will be interviewed by the prestigious MATWIN Board.
It takes place once a year in April in Paris.
Dr. Avenard is Board member or adviser for several companies and Chief Executive Officer of G1J-IDF, a seed venture fund in Life Sciences. From 1997 to 2010, he served as Chief Operating Officer of BioAlliance Pharma SA (BIO – NYSE-EURONEXT) since he co-founded the company. From 1990 to 1997, Dr. Avenard served as Medical Director of Development in the Cassenne Laboratories division of Hoechst Marion Roussel (Sanofi-Aventis Pharma).From 1976 to 1990, Dr. Avenard held various positions with the National Blood Transfusion Center in Paris, including Medical Director of Bio-Transfusion (LFB), providing human plasma products. He has also served as a physician in hemobiology and blood transfusion at the Blood Center of Pitié-Salpétrière Hospital in Paris. Dr. Avenard received his MD as well as degrees in hematology and hemobiology & blood transfusion from the School of Medicine at the University of Paris V. He is currently member of the Biotech Working Group at LEEM (pharmaceutical French trade association). He is also expert for Research Tax Credit at the Ministry of Research.
Jean-Yves Bonnefoy is CEO of Anagenesis Biotechnologies since January 2014. He is also President of the Life Sciences Competitiveness Cluster, Alsace BioValley, Board member of biotech companies Anagenesis and SILABE and of the engineer school ESBS. He is a member of the scientific advisory board of iTeos Therapeutics and Centre de Recherche des Cordeliers. He is also member of the investment committee of the TTO, SATT Conectus. Before Anagenesis Biotechnologies he co-founded Transgene Spin-off, ElsaLys Biotech. He was for 8 years VP, R&D of Transgene SA. From 2002 to 2005, he launched and managed the Canceropole Lyon Rhône-Alpes. From 1992 to 2002, he headed the Centre d’immunologie Pierre Fabre. From 1998 to 2002, he was Director of the Immunology Department of the Glaxo-Wellcome Institute in Switzerland. From 1985 to 1987, he was scientist at the Research Centre of Schering-Plough in France. He is author and co-author of more than 200 publications and reviews (H-index 55-30-13). Jean-Yves holds a PhD in Immunology, a “Thèse 3ème cycle” in Biochemistry and followed the Senior Management Program of the London Business School, in the UK.
Nicolas Foray, radiobiologist, Inserm researcher, is the head of the Radiobiology Group (UMR 1052 INSERM Unit (Cancer Research Centre of Lyon). His research projects imply the individual response to ionizing radiation and genotoxic stress and also the DNA damage repair. He is the author of 85 publications and books chapter in the field. He was awarded in 2009 by the National Academy of Sciences (Prix Peyré). Nicolas FORAY is the President of the French-speaking Radiobiology Society (SIRLaF) and President of the LOWRAD international conferences.
Dr. Herrera has more than 25 years of experience in the pharmaceutical industry with a strong focus in oncology drug development and marketing. Before setting up his own oncology consultancy – Alain Oncologie Consulting (AOC) -, he headed the global Oncology business at Sanofi for ten years, where he was Vice President for the Global Oncology Business Strategy and Development (2007-2008) and Head of the Global Oncology Franchise (1998-2007). He contributed to the worldwide registration of Oxaliplatin (Eloxatin®) and Rasburicase (Fasturtec®/Elitek®), as well as the Gastric and Head & Neck indications for Docetaxel (Taxotere®). His previous responsibilities within the pharmaceutical industry included the roles of Chairman and CEO of Chiron Therapeutics Europe, Managing Director at Pierre Fabre Oncology Laboratories and Head of the Oncology Platform at Roger Bellon (Rhône Poulenc). In addition to these roles, since 1991, Dr. Herrera has been a Hematologist Consultant at Antoine Beclere Hospital.
David PIQUEMAL Co-founder and Scientific Director of ACOBIOM Company. The Company was set-up in 1999 and located in Montpellier. Acobiom is specialized in discovery of new Biomarkers and in the development of innovative Diagnostics dedicated to Personalized Medicine / Precision Medicine / P4 Medicine. Also co-founder of the Computational Biology Institute in Montpellier (IBC, set-up in 2012, member of the steering committee): the institute aims at the development of innovative methods and software to analyze, integrate and contextualize large-scale biological data in the fields of health, agronomy and environment.
Grégoire Prévost is a Doctor in Cellular and Molecular Biology. He now has more than 30 years of experience in drug discovery in oncology and early phases of clinical development. Dr. Grégoire Prévost is the founder, owner and CEO of CIPREVO, an expertise provider company supporting innovation projects in the fight against cancer. CIPREVO is based in France and its main clients are Pharmas, CROs, Biotechnologies, Start-ups, Consortiums, Investors, Funds, University groups or patient associations. His expertise is recognized by the French government with the approval of the Research Tax Credit and the Empowerment to Direct Research (HDR). In addition, Grégoire Prévost is also the co-founder of the Sino-French School of Oncology in Wuhan (China). Previously, Grégoire Prévost was successively researcher at IOCMH (France), Director of Scientific Affairs at Ipsen-Beaufour and Chief Development Officer at Interna Technologies (Netherlands). He is the author of more than 65 international publications and 36 patent applications.
Isabelle Tabah-Fisch is a doctor specializing in oncology. She has held a number of key positions in the pharmaceutical industry (Schering-Plow, Sanofi), particularly as Development Project Manager and Medical Affairs Oncology World. With more than 25 years of experience, she has been actively involved in the clinical development, marketing, launching, patient access, marketing and commercialization of major anti-cancer drugs (oxaliplatin- Eloxatin®, docetaxel-Taxotere®, cabazitaxel-Jevtana®, aflibercept-Zaltrap®). She currently advises two pharmaceutical / biotech companies focused on oncology, CleveXel and PDC * line Pharma.
MATWIN Board interview :
Selected applicants submit their projects in front of the MATWIN International Board. This unique in Europe committee auditions the projects and labels those with the highest industrial development transfer potential. This committee’s feedback represents a significant added value for the project development.
Since 2017, MATWIN also invites investors (major venture capital firms, business angels, foundations…) to join the Board meeting. Those representatives can therefore benefit from a unique expertise feedback to detect projects with potential interest and maybe support financially their development.
The best (2-3) projects selected by the Board, could be offered the possibility of integrating a complementary support program that MATWIN is currently working on in order to maximize their intermediation potential.